March 25, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq ... today reported full year 2024 financial results and recent corporate updates. "In 2024, we reached key milestones that reinforced ...

President Donald Trump has repeatedly teased running for a third term in violation of the 22nd Amendment to the Constitution, ...

today reported full year 2024 financial results and recent corporate updates. HENDERSON, Nev., February 24, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset ...

Zura Bio holds an active Investigational New Drug with the U.S. Food and Drug Administration, allowing the clinical trial to proceed. Zura Bio plans to initiate a Phase 2 trial for the treatment ...

• Corporate actions are actions taken by a company that impact the shareholders’ value directly. It is an event that brings material changes to a company and affects its stakeholders ...

In September 2024, a third-party Contract Research Organization was selected to oversee and conduct the Phase 2 clinical program for HS. Zura Bio holds an active Investigational New Drug with the U.S.

Applicants seeking funding from the National Institutes of Health for, among other things, basic research, conferences, and ...

A global survey found most employees are overwhelmed by corporate vocabulary and clichés. But experts say there's a surprising social function behind all that officespeak. At a glance ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Ashley holds a bachelor's degree in multimedia journalism from Florida Atlantic University. Although commonly thought of interchangeably, corporate credit cards are actually their own product distinct ...

March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview ...

We prefer our contributors to use real-world examples from federal agencies in ... consultants and corporate leaders. We do not publish articles that seem to be aimed at promoting the fortunes ...